Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Coming soon
- Protocol: GSK219240
- Drug: Belimumab
- Sponsor: GlaxoSmithKline
- Description: A phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosis.
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Sclerosis
- Enrollment Status: Open
- Protocol: CVAY736S12201
- Drug: Ianalumab
- Sponsor: Novartis
- Description: A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis
Henry Ford Health System – Rheumatology
Primary Coordinator: Jenna Hudy 313-916-9328
- Indication: Vasculitis
- Enrollment Status: Open
- Protocol: 20220159
- Drug: Avacopan
- Sponsor: Amgen
- Description: A randomized, double-blind, placebo-controlled phase 4 clinical trial to evaluate the long-term safety and efficacy of Avacopan in subjects with Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
